COVID-19: vaccination vs. hospitalization
Objective Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Infection - 50(2022), 3 vom: 04. Jan., Seite 747-752 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Uzun, Oguz [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022 |
|---|
| doi: |
10.1007/s15010-021-01751-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR047143487 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047143487 | ||
| 003 | DE-627 | ||
| 005 | 20230519160717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220531s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-021-01751-1 |2 doi | |
| 035 | |a (DE-627)SPR047143487 | ||
| 035 | |a (SPR)s15010-021-01751-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Uzun, Oguz |e verfasserin |0 (orcid)0000-0002-0475-4198 |4 aut | |
| 245 | 1 | 0 | |a COVID-19: vaccination vs. hospitalization |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022 | ||
| 520 | |a Objective Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination. | ||
| 650 | 4 | |a COVID-19 pandemic |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SinoVac |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a BioNTech |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Akpolat, Tekin |4 aut | |
| 700 | 1 | |a Varol, Ayhan |4 aut | |
| 700 | 1 | |a Turan, Sema |4 aut | |
| 700 | 1 | |a Bektas, Serife Gokbulut |4 aut | |
| 700 | 1 | |a Cetinkaya, Pelin Duru |4 aut | |
| 700 | 1 | |a Dursun, Mazlum |4 aut | |
| 700 | 1 | |a Bakan, Nurten |4 aut | |
| 700 | 1 | |a Ketencioglu, Burcu Baran |4 aut | |
| 700 | 1 | |a Bayrak, Murat |4 aut | |
| 700 | 1 | |a Baris, Serap Argun |4 aut | |
| 700 | 1 | |a Guner, Rahmet |4 aut | |
| 700 | 1 | |a Gunal, Ozgur |4 aut | |
| 700 | 1 | |a Nural, Serkan |4 aut | |
| 700 | 1 | |a Deniz, Pelin Pinar |4 aut | |
| 700 | 1 | |a Toprak, Oya Baydar |4 aut | |
| 700 | 1 | |a Ozkan, Gulcihan |4 aut | |
| 700 | 1 | |a Gumus, Ayça |4 aut | |
| 700 | 1 | |a Kerget, Ferhan |4 aut | |
| 700 | 1 | |a Ercelik, Merve |4 aut | |
| 700 | 1 | |a Ataoglu, Ozlem |4 aut | |
| 700 | 1 | |a Yuksel, Aycan |4 aut | |
| 700 | 1 | |a Ates, Gungor |4 aut | |
| 700 | 1 | |a Kutsoylu, Oya Eren |4 aut | |
| 700 | 1 | |a Kose, Neslihan |4 aut | |
| 700 | 1 | |a Kizilirmak, Deniz |4 aut | |
| 700 | 1 | |a Keskin, Serdar |4 aut | |
| 700 | 1 | |a Gultekin, Okkes |4 aut | |
| 700 | 1 | |a Coskun, Nilüfer |4 aut | |
| 700 | 1 | |a Yilmaz, Emine Serap |4 aut | |
| 700 | 1 | |a Uslu, Selen |4 aut | |
| 700 | 1 | |a Basyigit, İlknur |4 aut | |
| 700 | 1 | |a Ergan, Begüm |4 aut | |
| 700 | 1 | |a Deveci, Figen |4 aut | |
| 700 | 1 | |a Yakar, Mehmet Nuri |4 aut | |
| 700 | 1 | |a Zuhur, Cigdem |4 aut | |
| 700 | 1 | |a Sagcan, Gulseren |4 aut | |
| 700 | 1 | |a Yuce, Zeynep Ture |4 aut | |
| 700 | 1 | |a Kuluozturk, Mutlu |4 aut | |
| 700 | 1 | |a Sezgin, Mehmet Emin |4 aut | |
| 700 | 1 | |a Sezgin, Esma Nur Aktepe |4 aut | |
| 700 | 1 | |a Havlucu, Yavuz |4 aut | |
| 700 | 1 | |a Cuhadaroglu, Caglar |4 aut | |
| 700 | 1 | |a Kilinc, Oguz |4 aut | |
| 700 | 1 | |a Boyaci, Hasim |4 aut | |
| 700 | 1 | |a Altunay, Hayriye |4 aut | |
| 700 | 1 | |a Akti, Mehmet |4 aut | |
| 700 | 1 | |a Dursun, Zehra Bastepe |4 aut | |
| 700 | 1 | |a Kalem, Ayse Kaya |4 aut | |
| 700 | 1 | |a Isik, Sinem Akkaya |4 aut | |
| 700 | 1 | |a Akyildiz, Levent |4 aut | |
| 700 | 1 | |a Aykac, Nilüfer |4 aut | |
| 700 | 1 | |a Almaz, Mehmet Selim |4 aut | |
| 700 | 1 | |a Kokturk, Nurdan |4 aut | |
| 700 | 1 | |a Itil, Oya |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d München : Urban & Vogel, 1973 |g 50(2022), 3 vom: 04. Jan., Seite 747-752 |w (DE-627)SPR032536909 |w (DE-600)2006315-5 |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2022 |g number:3 |g day:04 |g month:01 |g pages:747-752 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s15010-021-01751-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2022 |e 3 |b 04 |c 01 |h 747-752 | ||